Status:
COMPLETED
Long Term Safety Of GW685698X Via Nasal Biopsy
Lead Sponsor:
GlaxoSmithKline
Conditions:
Rhinitis, Allergic, Perennial
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Long term safety (52 weeks) of GW685698X on the nasal mucosa via nasal biopsy with an active control group (Nasonex®) and a healthy volunteers control group in subjects 18 years old with perennial all...
Detailed Description
A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray \[Nasonex®\] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqu...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- History of perennial allergic rhinitis of 2 years, with a documented positive allergen test to an appropriate allergen.
- Female patients of child-bearing potential must be willing to consistently and correctly use an acceptable method of birth control.
- Exclusion criteria:
- Patients who require certain medications for their allergy.
- Patients with serious medical problems.
Exclusion
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT00224523
Start Date
September 1 2005
End Date
February 1 2007
Last Update
October 28 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Leuven, Belgium, 3000
2
GSK Investigational Site
Amsterdam, Netherlands, 1105 AZ
3
GSK Investigational Site
Nijmegen, Netherlands, 6525 EX
4
GSK Investigational Site
The Hague, Netherlands, 2566 MJ